PDCA护理对恶性脑胶质瘤术后放疗联合替莫唑胺同期化疗所致不良反应患者生活质量的影响

目的：探讨PDCA护理对恶性脑胶质瘤术后放疗联合替莫唑胺同期化疗所致不良反应患者生活质量的影响。方法选取2011年10月-2013年10月沈阳军区总医院恶性脑胶质瘤术后放疗联合替莫唑胺同期化疗所致不良反应的患者28例，按随机数字法分为观察组与对照组，各14例，观察组给予PDCA护理，对照组给予一般常规护理，比较两组患者经护理后不良反应发生情况及生存质量评分。结果经过护理干预后，观察组恶性、呕吐等胃肠道反应占28.6%，骨髓抑制占7.2%，血液系统反应占14.3%，发生情况好于对照组（57.1%、21.4%、35.7%），差异均有统计学意义（均P〈0.05）。经过护理干预，观察组生存质量评分包括躯体功能、角色状态、社会功能、心理健康、疼痛、精力、体力（71.3±6.0）、（78.1±6.4）、（68.6±6.5）、（80.2±7.3）、（76.5±5.5）、（78.8±6.7）、（68.1±6.5）分]高于对照组躯体功能、角色状态、社会功能、心理健康、疼痛、精力、体力等生存质量评分（63.2±5.5）、（69.8±6.2）、（60.3±6.2）、（73.1±7.0）、（65.7±5.4）、（67.4±6.2）、（57.9±6.3）分]，差异均有统计学意义（均P〈0.05）。结论对恶性脑胶质瘤术后放疗联合替莫唑胺同期化疗所致不良反应的患者给予PDCA程序护理，可显著减少不良反应发生率，提高患者的生活质量。

Influence of PDCA care on the life quality of adverse reaction induced by malignant glioma combined Temozolomide concurrent chemotherapy in patients after radiotherapy

Objective To study the influence of PDCA care on the life quality of adverse reaction induced by malignant glioma combined Temozolomide concurrent chemotherapy in patients after radiotherapy. Methods From October 2011 to October 2013, 28 cases of patients in the General Hospital of Shenyang Military Region, with the same period with adverse reaction induced by malignant glioma combined Temozolomide concurrent chemotherapy in patients after ra-diotherapy, were divided into observation and control way according to the method of digital way, each had 14 cases. The observation group was given PDCA nursing, the control group was given conventional nursing care, two groups of patients after nursing adverse reaction conditions and the quality of life scores were compared. Results After nursing intervention, the observation group of gastrointestinal reactions such as malignant, vomiting （28.6%）, bone marrow sup-pression （7.2%）, blood system response （14.3%）, was better than the control group （57.1%, 21.4%, 35.7%）, the differ-ences were statistically significant （all P 〈 0.05）. After nursing intervention, quality of life score in the observation group of body function, role function, social function, mental health, pain, energy, physical were （71.3±6.0）, （78.1±6.4）, （68.6±6.5）, （80.2±7.3）, （76.5±5.5）, （78.8±6.7）, （68.1±6.5） scores, which were higher than control group in body function, role function, social function, mental health, pain, energy, physical （63.2±5.5）, （69.8±6.2）, （60.3±6.2）, （73.1±7.0）, （65.7±5.4）, （67.4±6.2）, （57.9±6.3） scores], the differences were statistically significant （all P 〈 0.05）. Conclusion Pa-tients after radiotherapy with malignant glioma combined Temozolomide concurrent chemotherapy with PDCA program care, can significantly reduce the incidence of adverse reaction, improve the quality of life of the patients.